The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia

Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USA.
Diabetes care (Impact Factor: 8.42). 09/2010; 33(9):2113-6. DOI: 10.2337/dc10-0357
Source: PubMed


To compare fenofibric acid (FA) + statin to respective monotherapies on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Post hoc analysis of over 2,000 metabolic syndrome patients administered either FA + low- or moderate-dose statin; FA alone; or low-, moderate-, or high-dose statin alone.
FA + low- or moderate-dose statin combination therapy reduced the presence of metabolic syndrome (35.7 or 35.9%, respectively) more than low-, moderate-, or high-dose statin monotherapy (15.5, 16.6, or 13.8%, respectively), mostly due to improvements in triglycerides and HDL cholesterol levels. Mean glucose levels slightly decreased with FA monotherapy, slightly increased with statin monotherapy, and were essentially unchanged with FA + statin. FA with or without statin also reduced non-HDL cholesterol, apolipoprotein B, total cholesterol, VLDL cholesterol, and high-sensitivity C-reactive protein.
FA + statin in patients with mixed dyslipidemia reduces the prevalence of metabolic syndrome.

Download full-text


Available from: Eli M Roth
  • Source
    • "Interestingly, the prevalence of patients meeting the fasting blood glucose criterion decreased slightly with FA + statin or FA monotherapy but increased slightly with the administration of statin monotherapy. Furthermore, the mean change in fasting glucose was significantly different between FA + low- or moderate-dose statin and low- or moderate-dose statin monotherapy, respectively (p ≤ 0.002) [31]. Statins have been associated with a slightly increased risk for T2DM development [33]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies. Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low- or moderate-dose statin. The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose. The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects. The FA and statin combination seems to be a reasonable option to further reduce cardiovascular risk in high-risk populations, although trials examining cardiovascular disease events are missing.
    Full-text · Article · May 2012 · Cardiovascular Drugs and Therapy
  • [Show abstract] [Hide abstract]
    ABSTRACT: The theoretical opportunity of creating chaotic generators is also investigated experimentally on the basis of two or more coupled one-transistor generators in the microwave range. The paper reports the design of transistor microwave oscillators in which it is possible to control the frequency band and the spectral characteristic is smooth. We show that the use of two and three coupled transistor auto-oscillators allows us to create microwave chaotic wide-band generators.
    No preview · Conference Paper · Oct 2004
  • [Show abstract] [Hide abstract]
    ABSTRACT: The chance discovery of hydroxymethylglutaryl (HMG)-CoA reductase inhibitors has revolutionized the care of patients with cardiovascular disease. The unexpected finding that these cholesterol-lowering drugs (or 'statins') also possess pleiotropic immunomodulatory properties, has opened a new area of research which investigates the anti-inflammatory and anti-proliferative properties of statins. In this brief commentary, we discuss the potential application of these drugs in asthma, where metabolic pathways pertinent to lung inflammation, in addition to the mevalonate cascade, may be targeted. We review mechanisms of action, discuss the potential therapeutic use of statins in asthma, share some preliminary data from our laboratory, discuss results from recent clinical trials in asthma, and propose a new target asthma subpopulation that could potentially benefit. We conclude our essay by highlighting the mevalonate-dependent and -independent pathways that may be modulated by statins, including the emerging area of cholesterol, sphingolipid, and lipid raft biology in lung disease. In this is an opportunity to develop new treatments for asthma, where innovative therapies are urgently needed to prevent acute exacerbations and alter disease progression.
    No preview · Article · Jan 2011
Show more

Similar Publications